StockMarketWire.com - Cancer and inflammatory diseases focused Tiziana Life Sciences said the US Food and Drug Administration had allowed the initiation of a clinical trial of a treatment for autoimmune and inflammatory diseases.
The Phase I clinical trial of the Foralumab treatment would be conducted in healthy volunteers using a novel oral enteric-coated capsule formulation in collaboration with the Brigham and Women's Hospital, Harvard Medical School, Boston.
'This is the first clinical trial in which Foralumab will be administered orally to healthy subjects,' the company said.
'Our objective is to develop orally administered Foralumab for treatment of autoimmune and inflammatory diseases.'
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.